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hypertension, the TAMRISK study
Kirsi Määttä, Tarja Kunnas* and Seppo T NikkariAbstract
Background: The rs41318021 polymorphism in the SLC7A1 gene affects endothelial NO production through
changes in L-arginine transport. This variation could thus hypothetically cause dysfunction of endothelium and lead
to hypertension. The association of rs41318021 with hypertension was therefore studied in a Finnish cohort.
Methods: A total of 412 hypertensive cases and 771 non-hypertensive controls from a Finnish 50-year-old cohort
were included in this study. The data was collected from the Tampere adult population cardiovascular risk study
(TAMRISK). DNA was extracted from buccal swabs and amplified using PCR. A subpopulation of men and women
who had available follow-up data of blood pressure measurements at the age of 35-, 40-, 45- and 50 years was also
analyzed.
Results: There was no difference between the variant frequencies of the hypertension group and normotensive
group at the age of 50 years (p = 0.209). However, repeated measures analysis from the 15-year follow-up showed
that subjects having gene variants CT or TT had slightly higher diastolic blood pressure than subjects having
genotype CC (p = 0.047). By post-hoc analysis, this was most pronounced at the age of 35 years (p = 0.044).
Conclusion: The rs41318021 polymorphism in the SLC7A1 gene was not associated with essential hypertension in
50-year-old subjects. However, a borderline effect of this variation upon diastolic blood pressure was seen in these
same subjects in a 15-year follow-up from a 35-year-old cohort to 50 years of age.Background
Hypertension is a disorder caused by a complex combi-
nation of genetic and lifestyle risk factors. Hypertension
raises the risk of incident cardiovascular disease to two-or
three-fold [1]. The major contributors to hypertension in
Western countries are overweight, physical inactivity, high
salt intake and low potassium intake [2]. The genetic com-
ponent in hypertension is estimated as 30 – 50% of the
total impact [3]. Candidate-gene and genome-wide associ-
ation studies (GWAS), have previously identified numer-
ous genetic loci that are associated with blood pressure,
but collectively these explain only a few percent of the
heritability for hypertension [4,5].
The role of vascular endothelium is significant in the
regulation of blood pressure. Endothelial cells synthesize
vasodilatory factors like nitric oxide (NO). Arginine is the
rate limiting substrate for endothelial nitric oxide synthase
(eNOS), which acts as a catalyst in NO production [6-8].* Correspondence: tarja.kunnas@uta.fi
Department of Medical Biochemistry, University of Tampere Medical School
and Fimlab laboratories, Tampere 33014, Finland
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reproduction in any medium, provided the orSLC7A1 (previously CAT-1), located in chromosome
13q12-q14, encodes a cationic amino acid transporter for
arginine and lysine uptake in mammalian cells [9,10].
Functional variation of SLC7A1 gene alters the expression
of SLC7A1, which may result in changes of NO pro-
duction and endothelial function [10]. Therefore, changes
in SLC7A1 gene could cause dysfunction of endothelium
and lead to hypertension.
To our knowledge, there is only one previous study that
has addressed the association of rs41318021 with hyper-
tension in an Australian population [10]. We wanted to
assess the role of this variant in a Finnish population, by
analyzing cohorts from the Tampere adult population car-
diovascular risk study (TAMRISK).Methods
Subjects
The data for the TAMRISK study was collected from peri-
odic health examinations (PHE) done for 50-year-old men
and women living in Tampere, Finland. TAMRISK data
includes information of risk factors for hypertension:Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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diseases, lipid values and smoking, diabetes and exercise
habits [11]. Buccal swabs for DNA extraction and a per-
missions form to use PHE data were collected by mail sep-
arately of the physical examination. The DNA samples
were collected during years 2006–2010. Informed consent
was obtained from all participants. The Ethics Commit-
tees of the Tampere University Hospital and the City of
Tampere approved the study.
Cases (n = 412) in this study were the subjects who
had hypertension at the age of 50 years (as diagnosed by
a physician) and for each case, at least one normotensive
control (n = 771) with the same sex and similar smoking
habits, were chosen from a PHE cohort (n = 6000).
Smoking status was evaluated based on self-reporting.
Finally, we selected a subpopulation of men and women
who had available data of blood pressure measurements
at the age of 35-, 40-, 45- and 50 years.Baseline measurements
The basic evaluation in 1988–91 included an interview
by a public health nurse. The interview was conducted
using a structured questionnaire about health and
health-related behaviour, including questions about
current and previous diseases. Information on current
and previous diseases was based on self-report of diag-
nosis by a physician, including history of coronary artery
disease, myocardial infarction and diabetes. Family his-
tory of hypertension in a close relative was also asked in
the questionnaire. The frequency of physical exercise
comprised both leisure and commute related activity.
Physical examination included a single blood pressure
(BP) measurement (mm of mercury) using a calibrated
mercury sphygmomanometer. Serum total cholesterol
(mmoles/litre), glucose (mmoles/litre) and haemoglobin
(grams/litre) were measured after an overnight fast by
standard techniques. Height (cm) and weight (kg) were
recorded from which the body mass index was calculated.Genotyping
DNA was extracted from buccal swabs using a commer-
cial kit (Qiagen Inc., Valencia, Calif., USA). Genotyping
was performed using allele specific primers: SLC7A
(047) 5′-AGT TGT CTG GAG GTG ACC-3′ and
SLC7A (050 T) 5′-GCAAGTGACGCACAGCCT-3′ or
SLC7A (049C) 5′-GCAAGTGAGGCACAGCCC-3′ as
described by Yang et al. (2007) [10]. Two parallel PCRs
were performed for each sample. Amplification was
done in 94°C for 15 minutes followed by 32 cycles of
94°C, 55°C and 72°C for 30 s each. The final extension
was at 72°C for 5 min. The PCR products were resolved
in 2% agarose gels.Statistical analysis
Analysis of variance (ANOVA) for continuous variables
and Chi-square test for categorical variables were ap-
plied for the comparison of cases and controls at the age
of 50 years. If the distribution was skewed, the analysis
was performed using transformed values to approxi-
mately normalize the distribution. To assess the effect of
risk factors for hypertension, we used binary logistic
(forwald wald) regression analysis. The analysis of vari-
ance for repeated measures was used to assess the differ-
ences in mean blood pressures between genotypes at the
age of 35-, 40-, 45- and 50 years. This follow-up data
was available from 775 participants.
P values less than 0.05 were considered significant.
Analyses were carried out using SPSS 16.0 for Windows
(SPSS Inc., Chicago, Illinois, USA).
Results
Clinical characteristics of the cases (412) and controls
(771) at the age of 50 years are presented in Table 1.
The case group of hypertensive subjects was compared
to healthy controls. Cases had higher body mass index
(BMI), haemoglobin (Hb), triglycerides, fasting glucose,
systolic and diastolic blood pressure, and lower HDL
cholesterol compared to controls. Cases exercised more
than controls and had higher frequency of diabetes,
myocardial infarction and family history of hypertension.
In the whole study population the frequencies of the
rs41318021 variants for SLC7A1 were 0.70 for CC (n =
828), 0.27 for CT (n = 319) and 0.03 (n = 36) for TT. There
was no difference between the variant frequencies of the
hypertension group and normotensive group (p = 0.209).
In the hypertension group the frequencies were 0.69 for
CC, 0.29 for CT and 0.02 for TT. In the control group
these proportions were 0.71, 0.26 and 0.03, respectively.
To find the explainable factors for hypertension in the
50-year-old cohort we analyzed the data using logistic
regression analysis. When SLC7A1 genotype, BMI, Hb,
HDL cholesterol, triglycerides, glucose, and family history
of hypertension were included in stepwise analysis (for-
ward wald), BMI, (p < 0.001, OR: 1.19, 95% CI 1.14-1.24),
glucose (p = 0.009, OR: 1.37, 95% CI: 1.08-1.75) and family
history of hypertension (p < 0.001, OR: 3.28, 95% CI: 2.35-
4.56) were associated with hypertension.
Finally we selected a subpopulation of men and women
in the present study who had available data of blood pres-
sure measurements at the age of 35-, 40-, 45- and 50 years.
This follow-up data was available from 775 participants,
with subjects from both the hypertension and control
groups. Subjects with CT and TT genotypes were com-
bined, because there were only 23 subjects in the TT
group. Repeated measures analysis showed that subjects
having gene variants CT or TT had slightly higher dia-
stolic blood pressure than subjects having genotype CC
Table 1 Clinical characteristics of study population at the age of 50 years
Cases (n = 412) Controls (n = 771) P
Age (years) 50 ± 0 50 ± 0
BMI (kg/m2) 28.6 ± 5.1 25.4 ± 3.6 <0.001
Haemoglobin (g/l) 147.2 ± 13.2 143.90 ± 13.6 <0.001
Cholesterol (mmol/l) 5.40 ± 0.97 5.40 ± 0.92 0.965
HDL cholesterol (mmol/l) 1.56 ± 0.45 1.67 ± 0.44 <0.001
LDL cholesterol (mmol/l) 3.17 ± 0.87 3.21 ± 0.84 0.512
Triglycerides (mmol/l) 1.55 ± 1.20 1.17 ± 0.68 <0.001
Glucose (mmol/l) 5.14 ± 1.20 4.84 ± 0.55 <0.000
Systolic blood pressure (mm Hg) 142.93 ± 16.17 129.75 ± 14.66 <0.000
Diastolic blood pressure (mm Hg) 92.92 ± 8.95 84.44 ± 9.40 <0.000
Exercise (at least twice a week) % 33.8 28.0 0.048
Diabetes % 11.8 0 <0.000
Myocardial infarction % 2.5 0 <0.000
Family history of hypertension % 71.3 42.2 <0.000
Current smoking % 19 19
Gender (male) % 58.4 56.8 0.319
Data are presented as mean ± SD.
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diastolic blood pressure was 1.4 mmHg at its highest at
the age of 35 years. The trend was similar for systolic
blood pressure, but not statistically significant (p = 0.234).
By one way ANOVA, the only statistical difference for
diastolic and systolic blood pressure between the geno-
types was for diastolic blood pressure at the age of 35 years
(p = 0.044).
When covariates that emerged as being significant in
the logistic regression at the age of 50 years (BMI and
glucose) were added to the repeated measures model,Figure 1 Means of systolic and diastolic blood pressures in follow-up
gene variants.the results remained the same in the follow-up. Subjects
having gene variants CT or TT had higher diastolic blood
pressure than subjects having genotype CC (p = 0.021).
Again, the trend for systolic blood pressure was not statis-
tically significant (p = 0.241).
Discussion
Gene variation rs41318021 in the human SLC7A1, which
encodes the principal arginine transporter, has previously
been proposed to associate with a genetic predisposition
to essential hypertension [10,12]. Our study subjects wereat the age of 35-, 40-, 45- and 50 years, according to SLC7A1
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25–64 year old adults have mean systolic pressure of
140 mmHg or above, which is among the highest in
Europe [2]. The association of rs41318021 with hyper-
tension was therefore studied in this Finnish cohort.
Environmental and genetic changes in L-arginine
transport are known to influence NO production sig-
nificantly. Endothelial NO formation is reduced in
subjects with essential hypertension, when compared to
normotensive subjects [12]. Synthesis of NO requires
substrate L-arginine [13]. Vasodilatation may be affected
by limitation of substrate (L-arginine) for the synthesis
of NO. The actual effect of decreased availability of
L-arginine on impaired endothelial function is still con-
troversy. Increasing age is associated with declining
endothelial function [14], which might explain some of
the differences between contradictory results on L-
arginine availability and hypertension [15,16].
L-arginine transporter SLC7A1 (previously CAT-1) has
an important role in L-arginine availability [8]. Yang and
Kaye [17] were able to show differences in gene expression
between alleles of the SLC7A1 gene (rs41318021). Using
reporter gene constructs they showed that minor allele T
in rs41318021 is associated with lower gene expression
compared with major allele C. They also found that there
was a difference in allele frequency between hypertensive
and normotensive subjects in an Australian population. In
hypertensive subjects the frequency of the T allele was
13.3%, compared with 7.6% in the normotensive subjects
(P < 0.001) [10,17].
The frequencies of the SLC7A1 gene variants in our
study population were similar to those reported previously
[10]. In contrast to the earlier study [10], polymorphism
rs41318021 in the SLC7A1 was not associated with essen-
tial hypertension in 50-year-old subjects. On the other
hand, a borderline effect of this variation was seen in these
same subjects from the age of 35 years. This is in line with
the conclusion that the effect of a single gene polymorph-
ism is seen more likely in a younger population [5]. The
observed effect of a single gene variation on blood pres-
sure in GWAS studies is low: +1.16 mmHg at the highest
[5], as also seen in the present study.
The background of hypertension consists of many genes
and moreover of gene-environment interactions. Ageing is
known to result in untoward increases in body mass index
in the TAMRISK study cohorts [11]. Thus, genetic effects
are more likely to be seen at younger ages. With aging,
other factors, e.g. overweight, may be somewhat more
relevant to development of hypertension.
Conclusions
In conclusion, the effect of gene variation rs41318021 in
the human SLC7A1 on blood pressure was of borderline
significance at the age of 35 years, and masked byenvironmental factors by the age of 50 years in the
TAMRISK study.
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